Floatz logo

Muromonab-Cd3

Hodgkin Disease

St. Jude Children's Research Hospitalmonoclonal_antibodyPhase 2Dormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Hodgkin Disease cohort.

Asset / SponsorPhaseRating
Vinorelbine
Michael Spinner, MD
Phase 3BBB
Plerixafor
Thomas Jefferson University
Phase 2BB
Favezelimab
Merck Sharp & Dohme LLC
Phase 2BB
PHOSPHONIC ACID, P-(2-(4-(6-AMINO-2-(((TRANS-4-(((3-(CYCLOHEXYLAMINO)PROPYL)AMINO)METHYL)CYCLOHEXYL)METHYL)AMINO)-4-PYRIMIDINYL)-1-PIPERAZINYL)ETHYL)-
GPCR Therapeutics, Inc.
Phase 2BB
Sgn-30
National Cancer Institute (NCI)
Phase 2BB

View all 40 →

Same molecule, other indications

Muromonab-Cd3 is also rated in:

acute lymphoblastic leukemiaDormant
BB
Indicative ·
69 / 100
View asset →
Myelodysplastic Syndrome (MDS)Dormant
BB
Indicative ·
69 / 100
View asset →
paroxysmal nocturnal hemoglobinuriaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →